Employing Effective Multidisciplinary Care to Reduce the Burden of Myelodysplastic Syndrome : Episode 10
Opinion
Video
Novel Therapy Impact on Patient Quality of Life
Novel therapies in MDS treatment are evaluated by a panel of experts led by Dr Haumschild.
Video Player is loading.
Related Videos
Overview of Treatment Landscape for IgA Nephropathy: Standard of Care and KDIGO Guidelines
Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing
Ruxolitinib Cream and Atopic Dermatitis at AAD 2025
Clinical Impact of IgA Nephropathy and Quality of Life
Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy
Population Outcomes and Return on Value With CGMs
Important Updates in the Management of Uncomplicated UTIs
Economic Burden Associated With Uncomplicated UTIs
Health Care Quality Impact
Related Content
